Media Coverage

Media Coverage
December 09, 2020
HOW CYTOAGENTS’ PLANS FOR GROWTH RUN FAR BEYOND COVID CRISIS

GP1681 “has the potential to be the next best practice in medicine in areas with significant unmet need,” CytoAgents CEO Teresa Whalen said.

Media Coverage
October 18, 2020
INTERVIEW WITH TERESA WHALEN, CEO – OUR REGION’S BUSINESS ON WPXI-TV

CytoAgents CEO, Teresa Whalen, RPh spoke with Bill Flanagan at WPXI-TV about our lead drug candidate GP1681 entering clinical trials. She discussed how GP1681 is designed to calm the “cytokine storm,” a condition triggered by COVID-19, influenza, and other respiratory viruses. Often,…

Media Coverage
May 14, 2020
PITTSBURGH BIOTECH COMPANY RECEIVES $1.6 MILLION GRANT TO DEVELOP DRUG TO TREAT COVID-19
Media Coverage
May 13, 2020
PITTSBURGH HAS LONG BEEN A LIFE SCIENCES ENGINE. NOW IT’S AT THE FOREFRONT OF COVID-19 VACCINE EFFORTS
Media Coverage
May 13, 2020
NORTH SHORE COMPANY GETS $1.6 MILLION GRANT FOR NEW DRUG DEVELOPMENT
Media Coverage
May 13, 2020
PITTSBURGH BIOTECH FIRM WINS NIH GRANT FOR COVID-19 CLINICAL TRIAL
Media Coverage
May 04, 2020
QUOTIENT SCIENCES, CYTOAGENTS FORM COVID-19 COLLABORATION
Media Coverage
March 14, 2020
CYTOAGENTS RECEIVES NIH FUNDING TO ACCELERATE TREATMENT FOR CYTOKINE STORM
Media Coverage
March 14, 2020
CYTOAGENTS GETS NIH FUNDING TO ADVANCE THERAPY FOR CYTOKINE STORM